BR112021017943A2 - Comprimido poroso de desintegração oral com poros microscópicos, e, método para preparar um comprimido poroso de desintegração oral com poros microscópicos - Google Patents

Comprimido poroso de desintegração oral com poros microscópicos, e, método para preparar um comprimido poroso de desintegração oral com poros microscópicos

Info

Publication number
BR112021017943A2
BR112021017943A2 BR112021017943A BR112021017943A BR112021017943A2 BR 112021017943 A2 BR112021017943 A2 BR 112021017943A2 BR 112021017943 A BR112021017943 A BR 112021017943A BR 112021017943 A BR112021017943 A BR 112021017943A BR 112021017943 A2 BR112021017943 A2 BR 112021017943A2
Authority
BR
Brazil
Prior art keywords
orally disintegrating
microscopic pores
disintegrating porous
porous tablet
preparing
Prior art date
Application number
BR112021017943A
Other languages
English (en)
Inventor
Courtney Bond
Jayne Bretti Laura
Paul Grother Leon
Thomas Fernandez
Original Assignee
Catalent Uk Swindon Zydis Ltd
Edenbridge Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent Uk Swindon Zydis Ltd, Edenbridge Pharmaceuticals Llc filed Critical Catalent Uk Swindon Zydis Ltd
Publication of BR112021017943A2 publication Critical patent/BR112021017943A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

comprimido poroso de desintegração oral com poros microscópicos, e, método para preparar um comprimido poroso de desintegração oral com poros microscópicos. os comprimidos porosos de desintegração oral com poros microscópicos compreendem uma quantidade eficaz de glicopirrolato com uma taxa de desintegração na boca de menos que 60 segundos e uma biodisponibilidade aumentada. métodos para tratar sialorreia, controlar produção excessiva de ácido estomacal, controlar sudorese excessiva, controlar dor estomacal e/ou abdominal e tratar arritmia induzida por drogas.
BR112021017943A 2019-03-12 2019-03-12 Comprimido poroso de desintegração oral com poros microscópicos, e, método para preparar um comprimido poroso de desintegração oral com poros microscópicos BR112021017943A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/021763 WO2020185214A1 (en) 2019-03-12 2019-03-12 Orally disintegrating tablets comprising glycopyrrolate and methods for increasing bioavailability

Publications (1)

Publication Number Publication Date
BR112021017943A2 true BR112021017943A2 (pt) 2021-11-16

Family

ID=72426450

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017943A BR112021017943A2 (pt) 2019-03-12 2019-03-12 Comprimido poroso de desintegração oral com poros microscópicos, e, método para preparar um comprimido poroso de desintegração oral com poros microscópicos

Country Status (7)

Country Link
US (1) US20210161824A1 (pt)
EP (1) EP3923931A4 (pt)
JP (1) JP2022533510A (pt)
KR (1) KR20210154964A (pt)
CN (1) CN113784711A (pt)
BR (1) BR112021017943A2 (pt)
WO (1) WO2020185214A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
US7091236B1 (en) * 2003-08-20 2006-08-15 Sciele Pharma, Inc. Method for increasing the bioavailability of glycopyrrolate
US20050101621A1 (en) * 2003-11-12 2005-05-12 Richard Lipsky Method for rapid detoxification of addiction
ES2277767B1 (es) * 2005-11-04 2008-04-01 Simbec Iberica, S.L. Formas orales solidas de ebastina.
WO2007074856A1 (ja) * 2005-12-28 2007-07-05 Takeda Pharmaceutical Company Limited 口腔内崩壊性固形製剤の製造法
CA2617688C (en) * 2007-02-22 2015-08-18 Alpex Pharma S.A. Solid dosage formulations containing weight-loss drugs
EP1980240A1 (en) * 2007-04-11 2008-10-15 Cephalon France Lyophilized pharmaceutical compositions and methods of making and using same
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
WO2011085181A1 (en) * 2010-01-08 2011-07-14 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
US20190083391A1 (en) * 2017-09-18 2019-03-21 Balto Therapeutics Orally disintegrating tablets for treatment of peptic ulcer

Also Published As

Publication number Publication date
KR20210154964A (ko) 2021-12-21
EP3923931A4 (en) 2022-10-26
JP2022533510A (ja) 2022-07-25
US20210161824A1 (en) 2021-06-03
WO2020185214A1 (en) 2020-09-17
EP3923931A1 (en) 2021-12-22
CN113784711A (zh) 2021-12-10

Similar Documents

Publication Publication Date Title
BR112015008139A2 (pt) formulação de forma de dosagem sólida de desintegração rápida compreendendo carbonato de cálcio funcionalizado e método de fabricação dos mesmos
WO2016070151A8 (en) Methods and compositions relating to microbial treatment and diagnosis of disorders
NO20081843L (no) Farmasoytisk sammensetning for forbedret kognitiv funksjon
MX2022016422A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
BRPI0518093A (pt) dose de nanopartìculas a um paciente, método de intensificação do transporte paracelular intestinal ou o transporte paracelular de sangue do cérebro e dose oral de nanopartìculas que intensifica o transporte paracelular intestinal ou o transporte paracelular de sangue do cérebro
MA33044B1 (fr) Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
MX2021002321A (es) Nuevos metodos.
MX2019003598A (es) Formulaciones orales de derivados de pirrolidina.
MY148878A (en) Stabilized amorphous forms of imatinib mesylate
UA96447C2 (ru) Полиморфные формы (2s)-(4e)-n-метил-5-[3-(5-изопропоксипиридин)ил]-4-пентен-2-амина для лечения расстройств центральной нервной системы
RU2014138035A (ru) Твердая фармацевтическая композиция, содержащая 1-(3-(2-(1-бензотиофен-5-ил)этокси)пропил)азетидин-3-ол или его соль
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
MX2020012377A (es) Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
EP4233913A3 (en) Improved bromocriptine formulations
BR112021017943A2 (pt) Comprimido poroso de desintegração oral com poros microscópicos, e, método para preparar um comprimido poroso de desintegração oral com poros microscópicos
SI1745010T1 (sl) Substituirani cikloheksil-1,4-diaminski derivati
MX2021008536A (es) Formulaciones en comprimidos de liberacion modificada que contienen inhibidores de fosfodiesterasa.
ATE526015T1 (de) Arzneimittel sowie deren herstellung und verwendung bei der behandlung von schmerzhaften neuropathien
MA38215A1 (fr) Composition pharmaceutique ophtalmologique topique contenant regorafenib
MA37524B1 (fr) Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee
MX2022004382A (es) Metodos para promover la produccion de scfa por microbiota intestinal.
WO2011060253A3 (en) Methods of treating diseases, pharmaceutical compositions, and pharmaceutical dosage forms
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
BR112014015620A2 (pt) comprimidos e agentes revestidos a seco

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2765 DE 02-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.